Please assess the completion status of the following clinical trial:

Trial Title: Magnesium Oxide in Treating Hot Flashes in Menopausal Women With Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Meets 1 of the following criteria:~  * History of breast cancer (currently without malignant disease)~ * No history of breast cancer but wishes to avoid estrogen due to a perceived increased risk of breast cancer~* Must have bothersome hot flashes (defined by their occurrence of ≥ 14 times per week and of sufficient severity to make the patient desire therapeutic intervention) for ≥ 1 month before study entry~* Has undergone treatment for cancer (patients other than breast cancer survivors are eligible)~PATIENT CHARACTERISTICS:~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Creatinine clearance ≥ 30 mL/min~* No hypersensitivity to magnesium oxide~* No medical or other condition(s) that, in the opinion of the investigator/sub-investigator, may compromise the objectives of the study~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* More than 4 weeks since prior and no concurrent antineoplastic chemotherapy, androgens, estrogens, progestational agents, or gabapentin~* More than 28 days since prior and no other concurrent investigational drugs~* Concurrent tamoxifen, raloxifene, or aromatase inhibitors allowed provided patient has been on a constant dose for \> 4 weeks AND is not expected to stop the medication during the study period

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Supportive care (magnesium oxide) (Type: EXPERIMENTAL): Patients receive magnesium oxide by mouth daily or twice daily for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).